ENTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.6M
+28.9%
3.5M
+16.3%
3.0M
-6.6%
3.3M
+22.0%
2.7M
R&D
3.2M
+42.2%
2.3M
+31.0%
1.7M
+4.6%
1.6M
+8.1%
1.5M
SG&A
1.4M
+5.7%
1.3M
-2.7%
1.3M
-17.9%
1.6M
+40.5%
1.1M
Operating Income
-4563000
-28.9%
-3539000
-16.3%
-3042000
+6.6%
-3256000
-22.0%
-2668000
EBITDA
-4554000
-28.9%
-3532000
-16.4%
-3035000
+6.6%
-3248000
-22.1%
-2661000
Net Income
-7312000
-108.6%
-3505000
-16.2%
-3016000
+5.8%
-3200000
-20.5%
-2656000
EPS (Basic)
$-0.14
-100.0%
$-0.07
-16.7%
$-0.06
+14.3%
$-0.07
-16.7%
$-0.06
EPS (Diluted)
$-0.14
-100.0%
$-0.07
-16.7%
$-0.06
+14.3%
$-0.07
-16.7%
$-0.06
Shares (Diluted)
50.5M
+5.6%
47.8M
+0.6%
47.5M
+0.8%
47.1M
+0.5%
46.8M
Entera Bio (ENTX) โ€” Financials